Professor of Psychiatry, NYU School of Medicine
Psychiatry
Dr. Donald C. Goff, MD
|
|
Give Review
Donald C. Goff is an expert in the field of Psychiatry. He went to David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is one of the top medical schools in the US. David Geffen School of Medicine at UCLA is ranked 13/7 in Research/PrimaryCare. He received awards:"Top Doctors: New York Metro Area", "America's Top Doctors", "Boston Magazine" and "Super Doctor". Donald C. Goff is also published. He has 92 publications published. The lastest publication: "Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment.'
Publications
- Abnormal white matter microstructure in Drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment.
- A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable Schizophrenia subjects on antipsychotic therapy.
- The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of Schizophrenia.
- Maintenance treatment with long-acting injectable antipsychotics: comparing old with new.
- Bitopertin: The Good News and Bad News.
- d-Cycloserine augmentation of cognitive remediation in Schizophrenia.
- Maintenance treatment with varenicline for smoking cessation in patients with Schizophrenia and bipolar disorder: a randomized clinical trial.
- High-dose oral ziprasidone versus conventional dosing in Schizophrenia patients with residual symptoms: the ZEBRAS study.
- Randomized multicenter investigation of folate plus vitamin B12 supplementation in Schizophrenia.
- No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with Schizophrenia.
- No Effect of Adjunctive, Repeated-Dose Intranasal Insulin Treatment on Psychopathology and Cognition in Patients With Schizophrenia.
- Anomalous Use of Context During Task Preparation in Schizophrenia: A Magnetoencephalography Study.
- Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia.
- Lack of insula reactivity to aversive stimuli in Schizophrenia.
- Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with Schizophrenia.
- Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial.
- Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in Schizophrenia.
- Genetic Variation Throughout the Folate Metabolic Pathway Influences Negative Symptom Severity in Schizophrenia.
- Reduced Sleep Spindles and Spindle Coherence in Schizophrenia: Mechanisms of Impaired Memory Consolidation?
- Abnormally persistent fMRI activation during antisaccades in Schizophrenia: A neural correlate of perseveration?
- Antipsychotic polypharmacy: are two ever better than one?
- d-cycloserine facilitation of cognitive behavioral therapy for delusions in Schizophrenia.
- Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with Schizophrenia.
- No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with Schizophrenia.
- Treatment adherence in Schizophrenia and schizoaffective disorder.
- An anterior-to-posterior shift in midline cortical activity in Schizophrenia during self-reflection.
- A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with Schizophrenia.
- MTHFR 677C>T effects on anterior cingulate structure and function during response monitoring in Schizophrenia: a preliminary study.
- A Hypomethylating Variant of MTHFR, 677C>T, Blunts the Neural Response to Errors in Patients with Schizophrenia and Healthy Individuals.
- Selective emotional processing deficits to social vignettes in Schizophrenia: an ERP study.
- Dysfunction of a cortical midline network during emotional appraisals in Schizophrenia.
- The treatment of cognitive impairment in Schizophrenia.
- Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with Schizophrenia on clozapine or risperidone.
- Strategies for improving treatment adherence in Schizophrenia and schizoaffective disorder.
- Inflammatory markers in Schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
- Modafinil for clozapine-treated Schizophrenia patients: a double-blind, placebo-controlled pilot trial.
- A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for Schizophrenia or schizoaffective disorder inadequately treate...
- Aberrant frontoparietal function during recognition memory in Schizophrenia: a multimodal neuroimaging investigation.
- Family-directed cognitive adaptation for Schizophrenia.
- Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with Schizophrenia treated with clozapine but not olanzapine.
- Aripiprazole added to overweight and obese olanzapine-treated Schizophrenia patients.
- Extinction memory is impaired in Schizophrenia.
- MTHFR 677C --> T genotype disrupts prefrontal function in Schizophrenia through an interaction with COMT 158Val --> Met.
- Predictors of early abstinence in smokers with Schizophrenia.
- Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in Schizophrenia.
- New insights into clinical response in Schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life.
- A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence.
- Varenicline treatment for smokers with Schizophrenia: a case series.
- The effects of transdermal nicotine on cognition in nonsmokers with Schizophrenia and nonpsychiatric controls.
- A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in Schizophrenia.
- Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in Schizophrenia.
- Lamotrigine as add-on therapy in Schizophrenia: results of 2 placebo-controlled trials.
- Hepatitis C in Schizophrenia: screening experience in a community-dwelling clozapine cohort.
- The evaluation and management of patients with first-episode Schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis.
- Reduced microstructural integrity of the white matter underlying anterior cingulate cortex is associated with increased saccadic latency in Schizophrenia.
- A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in Schizophrenia.
- Integrating general health care in private community psychiatry practice.
- Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in Schizophrenia patients receiving atypical antipsychotics.
- Catatonic coma with profound bradycardia.
- Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic Schizophrenia patients.
- Treatment of cardiac risk factors among patients with Schizophrenia and diabetes.
- Glucose metabolism in patients with Schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model anal...
- Dietary intake profile of patients with Schizophrenia.
- Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in Schizophrenia.
- Pharmacologic implications of neurobiological models of Schizophrenia.
- Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
- Independent effects of tobacco abstinence and bupropion on cognitive function in Schizophrenia.
- A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in Schizophrenia.
- Sustained activation of the hippocampus in response to fearful faces in Schizophrenia.
- A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
- Adverse cardiac effects associated with clozapine.
- Medical morbidity and mortality in Schizophrenia: guidelines for psychiatrists.
- What is perseverated in Schizophrenia? Evidence of abnormal response plasticity in the saccadic system.
- Glucose metabolism in patients with Schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model...
- A failure of sleep-dependent procedural learning in chronic, medicated Schizophrenia.
- Attitudes of Schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.
- Folate, homocysteine, and negative symptoms in Schizophrenia.
- Anterior cingulate cortex activation during cognitive interference in Schizophrenia.
- Two-year follow-up of a smoking cessation trial in patients with Schizophrenia: increased rates of smoking cessation and reduction.
- Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series.
- Clinical characteristics, cognitive functioning, and criminal histories of outpatients with Schizophrenia.
- Polypharmacy in Schizophrenia: a fuzzy concept.
- Impaired hippocampal recruitment during normal modulation of memory performance in Schizophrenia.
- Intact suppression of increased false recognition in Schizophrenia.
- Motor cortical excitability in Schizophrenia.
- A 23-year-old man with Schizophrenia.
- Schizophrenic subjects show deficient inhibition but intact task switching on saccadic tasks.
- Antisaccades and task switching: studies of control processes in saccadic function in normal subjects and schizophrenic patients.
- Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.
- Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles.
- Dissociable genetic contributions to error processing: a multimodal neuroimaging study.
Schools
University of California At Los Angeles
Cedars Sinai Med Center
Mass Genl Hospital
Tufts New England Med Center
Conditions Treated
- Nondependent Drug and Alcohol Abuse
- Schizophrenia
- Schizophreniform and Schizoaffective Disorder
Doctors Specialties
- Psychiatry
Accepted Insurances
Awards
- Top Doctors: New York Metro Area
- America's Top Doctors
- Boston Magazine
- Super Doctor
Education
-
Tufts Medical Center -
Massachusetts General Hospital -
Cedars-Sinai Medical Center -
David Geffen School of Medicine at UCLA
Hospital
-
NYU Langone Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Daniel B. Gadish, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Theodore A. Stern, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sherese Ali, MD |
|
|
Dr. Aisha Usmani, PHD |
|
|
Dr. Deborah R. Friedman, PHD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Antonio E. Bullon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matcheri S. Keshavan, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Chaya G. Bhuvaneswaran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert J. Levine, MD |
|
|
Dr. Raymond Serrano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cristina Montalvo, MD |
|
|
Dr. Yohanis L. Anglero Diaz, MD |